Avidity Partners 13F holdings, Q2 2020
Holdings as of June 30, 2020 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 57 US equity positions worth $1.6bn in its Q2 2020 13F filing. The largest position was ABBV at 9.7% of the reported book, followed by REGN and BIOHAVEN PHARMACTL HLDG CO L. Against the Q1 2020 filing, it opened 27 new positions, added to 19 and reduced 4 among the top 50 holdings.
What did Avidity Partners own in Q2 2020? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2020 |
|---|---|---|---|---|---|---|---|
| 1 | ABBV ABBVIE INC | Healthcare | 9.7% | $151.7m | 1,545,400 | 224% | added |
| 2 | REGN REGENERON PHARMACEUTICALS | Healthcare | 5.3% | $82.4m | 132,100 | 164% | added |
| 3 | BIOHAVEN PHARMACTL HLDG CO L | 5.2% | $80.8m | 1,104,500 | 105% | added | |
| 4 | BAX BAXTER INTL INC | Healthcare | 4.4% | $69.0m | 800,900 | – | new |
| 5 | IMMU IMMUNOMEDICS INC | 4.3% | $67.7m | 1,911,300 | 288% | added | |
| 6 | EXEL EXELIXIS INC | Healthcare | 4.1% | $64.0m | 2,694,070 | 148% | added |
| 7 | ALXN ALEXION PHARMACEUTICALS INC | 3.7% | $57.0m | 507,700 | 217% | added | |
| 8 | HO1 HOLOGIC INC | 3.0% | $46.6m | 817,200 | – | new | |
| 9 | SEATTLE GENETICS INC | 2.7% | $42.6m | 250,900 | -57% | reduced | |
| 10 | AUPH AURINIA PHARMACEUTICALS INC | Healthcare | 2.6% | $40.2m | 2,474,599 | 109% | added |
| 11 | MNTA MOMENTA PHARMACEUTICALS INC | 2.5% | $38.3m | 1,150,000 | 47% | added | |
| 12 | CHEMOCENTRYX INC | 2.4% | $37.2m | 645,800 | 174% | added | |
| 13 | ARVN ARVINAS INC | Healthcare | 2.3% | $36.1m | 1,076,900 | – | new |
| 14 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 2.1% | $33.3m | 404,900 | 106% | added |
| 15 | KDMN KADMON HLDGS INC | 2.1% | $32.9m | 6,426,700 | 127% | added | |
| 16 | PRINCIPIA BIOPHARMA INC | 2.1% | $32.8m | 548,500 | – | new | |
| 17 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 2.1% | $32.4m | 674,487 | – | new |
| 18 | HORIZON THERAPEUTICS PUB LTD | 1.9% | $29.8m | 536,200 | 61% | added | |
| 19 | ESPERION THERAPEUTICS INC NE | 1.8% | $28.7m | 559,700 | 173% | added | |
| 20 | AVTR AVANTOR INC | Healthcare | 1.8% | $27.4m | 1,612,000 | – | new |
| 21 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 1.6% | $25.4m | 620,600 | – | new |
| 22 | MERSANA THERAPEUTICS INC | 1.6% | $25.0m | 1,069,600 | – | new | |
| 23 | DVAX DYNAVAX TECHNOLOGIES CORP | 1.5% | $23.7m | 2,674,154 | -30% | reduced | |
| 24 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.5% | $22.6m | 1,527,400 | – | new |
| 25 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 1.4% | $22.6m | 185,100 | 89% | added |
| 26 | 8IN SYNEOS HEALTH INC | 1.4% | $21.3m | 366,500 | – | new | |
| 27 | BRISTOL-MYERS SQUIBB CO | 1.3% | $20.7m | 5,786,941 | – | new | |
| 28 | BTAI BIOXCEL THERAPEUTICS INC | 1.3% | $20.6m | 388,095 | 84% | added | |
| 29 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 1.3% | $20.3m | 738,547 | – | new |
| 30 | CRSP CRISPR THERAPEUTICS AG | Healthcare | 1.3% | $20.2m | 274,300 | – | new |
| 31 | HARPOON THERAPEUTICS INC | 1.3% | $20.0m | 1,206,351 | – | new | |
| 32 | MCK MCKESSON CORP | Healthcare | 1.3% | $19.6m | 128,000 | -47% | reduced |
| 33 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.2% | $18.9m | 1,331,100 | – | new |
| 34 | CHRS COHERUS BIOSCIENCES INC | Healthcare | 1.2% | $18.3m | 1,023,500 | 168% | added |
| 35 | EDIT EDITAS MEDICINE INC | Healthcare | 1.1% | $17.7m | 600,000 | – | new |
| 36 | ASND ASCENDIS PHARMA A S | Healthcare | 1.1% | $17.6m | 118,900 | 98% | added |
| 37 | AZN ASTRAZENECA PLC | Healthcare | 1.1% | $17.2m | 325,990 | – | new |
| 38 | ALEC ALECTOR INC | Healthcare | 1.1% | $16.8m | 686,400 | -4% | reduced |
| 39 | MDT MEDTRONIC PLC | Healthcare | 1.0% | $15.9m | 173,700 | – | new |
| 40 | PREVAIL THERAPEUTICS INC | 1.0% | $15.3m | 1,028,800 | – | new | |
| 41 | RCUS ARCUS BIOSCIENCES INC | Healthcare | 0.9% | $14.6m | 589,000 | – | new |
| 42 | ADAPY ADAPTIMMUNE THERAPEUTICS PLC | Healthcare | 0.9% | $14.4m | 1,438,000 | – | new |
| 43 | ANIK ANIKA THERAPEUTICS INC | Healthcare | 0.9% | $13.7m | 362,490 | 116% | added |
| 44 | RPRX ROYALTY PHARMA PLC | Healthcare | 0.6% | $9.7m | 200,000 | – | new |
| 45 | SURFACE ONCOLOGY INC | 0.6% | $9.7m | 1,478,699 | – | new | |
| 46 | DECIPHERA PHARMACEUTICALS IN | 0.6% | $9.3m | 156,266 | – | new | |
| 47 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 0.6% | $8.8m | 418,178 | – | new |
| 48 | VSTM VERASTEM INC | Healthcare | 0.5% | $7.6m | 4,414,991 | 58% | added |
| 49 | 1LIFE HEALTHCARE INC | 0.5% | $7.3m | 200,000 | – | new | |
| 50 | AKOUOS INC | 0.5% | $7.1m | 315,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.